Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 5,353 matching trials from the live ClinicalTrials.gov search.

Filters: Milwaukee, Wisconsin Clear all

Conditions: Neuroendocrine Tumors
Interventions: fosbretabulin tromethamine; Drug
Lead sponsor: Mateon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Stanford, California • Lexington, Kentucky • The Bronx, New York + 2 more

Conditions: Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexual Dysfunction
Interventions: 36.25 Gy IMRT, 51.6 Gy IMRT; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 32
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 25 more

Conditions: Leukemia
Interventions: rituximab, fludarabine phosphate; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 379
States / cities: Anniston, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 247 more

Conditions: Spinal Cord Injury (SCI)
Interventions: Elezanumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 22
States / cities: Sacramento, California • Atlanta, Georgia • Chicago, Illinois + 15 more

Conditions: Glioblastoma
Interventions: Gallium maltolate (500 mg), Gallium maltolate (1,000 mg), Gallium maltolate (1,500 mg), Gallium maltolate (2,000 mg), Gallium maltolate (2,500 mg), Gallium maltolate (recommended phase 2 dose); Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 42
States / cities: Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more

Conditions: Oral Leukoplakia
Interventions: aminolevulinic acid hydrochloride, photodynamic therapy, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 4
States / cities: Chicago, Illinois • Milwaukee, Wisconsin

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: tesevatinib; Drug
Lead sponsor: Kadmon Corporation, LLC; Industry
Eligibility: 18 Years to 62 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • St Louis, Missouri + 3 more

Conditions: Multiple Myeloma
Interventions: GCS-100, Bortezomib/Dexamethasone; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Gainesville, Florida • Boston, Massachusetts • Milwaukee, Wisconsin

Conditions: Transplant
Interventions: OCS Heart System; Device
Lead sponsor: TransMedics; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 27
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 20 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: BMS-986365, Enzalutamide, Abiraterone, Docetaxel, Predinsone/Prednisolone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 48
States / cities: Birmingham, Alabama • Gilbert, Arizona • Anaheim, California + 34 more

Conditions: Arthritis, Unstable Radial Head, Proximal Radioulnar Joint Instability, Decreased Motion at the Proximal Radioulnar Joint and/or the Radio-humeral Joint
Interventions: Aptis PRUJ Prosthesis; Device
Lead sponsor: Aptis Medical; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 7
States / cities: Carmel, Indiana • Louisville, Kentucky • Boston, Massachusetts + 4 more

Conditions: Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma
Interventions: Lenalidomide, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 113
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more

Conditions: Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7
Interventions: 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine, Chemotherapy, Computed Tomography, Erlotinib Hydrochloride, Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Quality-of-Life Assessment, X-Ray Imaging; Radiation · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 678
States / cities: Mobile, Alabama • Anchorage, Alaska • Auburn, California + 438 more

Conditions: Persian Gulf Syndrome, Mycoplasma Infections
Interventions: Doxycycline (200mg/day) or Placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2001
U.S. locations: 26
States / cities: Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 23 more

Conditions: Stroke
Interventions: Sentinel® Cerebral Protection System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 41
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 37 more

Conditions: Thrombocytopenia
Interventions: Avatrombopag 60 mg; Drug
Lead sponsor: Sobi, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 27
States / cities: Little Rock, Arkansas • Coronado, California • Aurora, Colorado + 22 more

Conditions: Post-Traumatic Stress Disorders
Interventions: Floatation-based reduced environmental stimulation therapy; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Cervical Spinal Cord Injury, Spine Injury, Cervical Spine Injury
Interventions: HuCNS-SC cells; Drug
Lead sponsor: StemCells, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Downey, California • Miami, Florida • Chicago, Illinois + 9 more

Conditions: Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
Interventions: Capecitabine, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin, Oxaliplatin, Pembrolizumab, Veliparib; Drug · Radiation · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 645
States / cities: Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 449 more

Conditions: Learning
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Not listed
Enrollment: 198 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: AML
Interventions: Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose, Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose, Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose, Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose, Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose, Ruxolitinib, Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose; Biological · Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 20
States / cities: Duarte, California • La Jolla, California • San Francisco, California + 16 more

Conditions: Persistent Pulmonary Hypertension of the Newborn
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Up to 12 Months
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Antibody-mediated Rejection
Interventions: Felzartamab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 26
States / cities: Los Angeles, California • Orange, California • San Bernardino, California + 20 more

Search by objective public record fields.

A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

Radiation Therapy in Treating Patients With Prostate Cancer

Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma

OCS Heart Perfusion Post-Approval Registry

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders.

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Antibiotic Treatment of Gulf War Veterans' Illnesses

PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement

Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure

The Feasibility and Examination of the Effects of Floatation-based REST on a Community Sample With PTSD

Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

The Use of Computer-Assisted Learning Pediatrics Program (CLIPP) in the Pediatric Clerkship

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)